Nektar Therapeutics is a leading biopharmaceutical company developing a robust pipeline of novel therapeutics based on its advanced polymer conjugate chemistry technology platform. Nektar also partners with the top biopharmaceutical companies to bring new products to market. To date, Nektar's technology and drug development expertise have enabled seven approved products for partners, which include leading biopharmaceutical companies.

News May 2, 2012 Nektar Therapeutics Reports Financial Results for the First Quarter of 2012 » Apr 25, 2012 Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets » Apr 10, 2012 Nektar to Host Investor and Analyst R&D Day in New York City » Apr 2, 2012 Nektar Doses First Subjects in Phase 1 Clinical Study Evaluating NKTR-192, a New Short-Acting Opioid Molecule for the Treatment of Acute Pain »

Contact Nektar investor relations Jennifer Ruddock Vice President of Investor Relations and Corporate Affairs 415-482-5585 Contact